Novel polydatin-loaded chitosan nanoparticles for safe and efficient type 2 diabetes therapy: In silico, in vitro and in vivo approaches

Abdel-Moneim, Adel; El-Shahawy, Ahmed A. G.; Yousef, Ahmed I.; El‐Twab, Sanaa M. Abd; Elden, Zienab Essam; Taha, Mohamed

doi:10.1016/j.ijbiomac.2019.11.031

Cited by 45 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the number of people with DM and its complications is increasing globally ( Vieira et al, 2019 ). The number of adult diabetic patients could increase from 425 million aged 20–79 years in 2017 to 693 million by 2045 ( Cho et al, 2018 ; Abdel-Moneim et al, 2020 ). There are two types of DM: type 1 DM (T1DM) and T2DM, and the latter accounts for more than 90% of all DM cases ( Nederstigt et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Agriophyllum Oligosaccharides Ameliorate Diabetic Insulin Resistance Through INS-R/IRS/Glut4-Mediated Insulin Pathway in db/db Mice and MIN6 Cells

et al. 2021

View full text Add to dashboard Cite

We have previously reported that Agriophyllum oligosaccharides (AOS) significantly enhance glycemic control by increasing the activation of insulin receptor (INS-R), insulin receptor substrate-2 (IRS-2), phosphatidylinositol 3 kinase (PI3K), protein kinase B (AKT), peroxisome proliferator-activated receptor (PPAR)-γ, and glucose transporter 4 (Glut4) proteins in hepatic tissues. However, the effect of glucose control by AOS on the regulation of pancreatic tissues in db/db mice and MIN6 cells remains to be determined. An oral dose of AOS (380 or 750 mg/kg) was administered to type-2 diabetic db/db mice for 8 weeks to determine whether AOS regulates glucose by the INS-R/IRS/Glut4-mediated insulin pathway. Meanwhile, the effects of AOS on glucose uptake and its related signaling pathway in MIN6 cells were also investigated. The results showed that the random blood glucose (RBG) level in the AOS-treated group was lower than that in the control group. AOS reduced the levels of glycated hemoglobin (HbA1c) and free fatty acid (FFA) and significantly improved the pathological changes in the pancreatic tissues in db/db mice. Moreover, immunohistochemical analysis revealed that the expression of INS-R, IRS-1, IRS-2, and Glut4 was increased in the AOS-treated group than in the model group. Further, in vitro experiments using MIN6 cells showed that AOS regulated INS-R, IRS-1, IRS-2, and Glut4 protein and mRNA levels and attenuated insulin resistance and cell apoptosis. The results of both in vitro and in vivo experiments were comparable. Ultra-performance liquid chromatography coupled with time-of-flight mass spectrometric analysis of AOS with precolumn derivatization with 3-amino-9-ethylcarbazole (AEC) tentatively identified five types of sugars: glucose, lactose, rutinose, glucuronic acid, and maltotriose. Our present study clearly showed that AOS is efficacious in preventing hyperglycemia, possibly by increasing insulin sensitivity and improving IR by regulating the INS-R/IRS/Glut4 insulin signal pathway. Therefore, AOS may be considered as a potential drug for diabetes treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Agriophyllum Oligosaccharides Ameliorate Diabetic Insulin Resistance Through INS-R/IRS/Glut4-Mediated Insulin Pathway in db/db Mice and MIN6 Cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Abdel-Moneim et al [164] were the first to develop and investigate a novel oral formula of polydatin-loaded chitosan nanoparticles (PD-CS NPs) to improve the therapeutic potential of PD against type 2 diabetes. The in vivo study revealed that PD-CSNPs exhibited significant antidiabetic efficacy in diabetic rats compared to free PD.…”

Section: Antidiabetic Drugsmentioning

confidence: 99%

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Mikušová

Mikuš

2021

IJMS

184

View full text Add to dashboard Cite

Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug carriers because of some intrinsic beneficial properties including biocompatibility, biodegradability, non-toxicity, bioactivity, easy preparation, and targeting specificity. Drug transport and release from CS-based particulate systems depend on the extent of cross-linking, morphology, size, and density of the particulate system, as well as physicochemical properties of the drug. All these aspects have to be considered when developing new CS-based NPs as potential drug delivery systems. This comprehensive review is summarizing and discussing recent advances in CS-based NPs being developed and examined for drug delivery. From this point of view, an enhancement of CS properties by its modification is presented. An enhancement in drug delivery by CS NPs is discussed in detail focusing on (i) a brief summarization of basic characteristics of CS NPs, (ii) a categorization of preparation procedures used for CS NPs involving also recent improvements in production schemes of conventional as well as novel CS NPs, (iii) a categorization and evaluation of CS-based-nanocomposites involving their production schemes with organic polymers and inorganic material, and (iv) very recent implementations of CS NPs and nanocomposites in drug delivery.

show abstract

“…Nanomedicine is the medicinal use of nanotechnology that employs biocompatible, low-toxicity nanomaterials and nanoparticles to control drug pharmacokinetics, administration rate, and bioavailability [ 96 ]. In addition, polydatin may guard against brain injury, kidney problems, heart failure, and improve glucose and lipid metabolism [ 97 , 98 ]. However, therapeutic activities of polydatin are constrained due to weak water solubility, the chemical imbalance in aqueous alkaline medium, and substantial first-pass metabolism.…”

Section: Polydatin Novel Delivery Systems: Nanoformulations and Targeted Therapymentioning

confidence: 99%

“…In diabetes mellitus (DM), polydatin was used because of its various therapeutic mechanisms consisting of controlling free-radical production and mitochondrial activity, as well as regulation of inflammation and oxidative stress [ 97 , 98 ]. The anti-hyperglycemic and antioxidant effects of polydatin resulted in a substantial reduction in hemoglobin A1C in treated diabetic rats, and treatment resulted in a significant increase in hepatic glycogen levels, which may be secondary to improved insulin levels and intervention [ 98 ].…”

Section: Polydatin Novel Delivery Systems: Nanoformulations and Targeted Therapymentioning

confidence: 99%

The Neuroprotective Role of Polydatin: Neuropharmacological Mechanisms, Molecular Targets, Therapeutic Potentials, and Clinical Perspective

et al. 2021

View full text Add to dashboard Cite

Neurodegenerative diseases (NDDs) are one of the leading causes of death and disability in humans. From a mechanistic perspective, the complexity of pathophysiological mechanisms contributes to NDDs. Therefore, there is an urgency to provide novel multi-target agents towards the simultaneous modulation of dysregulated pathways against NDDs. Besides, their lack of effectiveness and associated side effects have contributed to the lack of conventional therapies as suitable therapeutic agents. Prevailing reports have introduced plant secondary metabolites as promising multi-target agents in combating NDDs. Polydatin is a natural phenolic compound, employing potential mechanisms in fighting NDDs. It is considered an auspicious phytochemical in modulating neuroinflammatory/apoptotic/autophagy/oxidative stress signaling mediators such as nuclear factor-κB (NF-κB), NF-E2–related factor 2 (Nrf2)/antioxidant response elements (ARE), matrix metalloproteinase (MMPs), interleukins (ILs), phosphoinositide 3-kinases (PI3K)/protein kinase B (Akt), and the extracellular regulated kinase (ERK)/mitogen-activated protein kinase (MAPK). Accordingly, polydatin potentially counteracts Alzheimer’s disease, cognition/memory dysfunction, Parkinson’s disease, brain/spinal cord injuries, ischemic stroke, and miscellaneous neuronal dysfunctionalities. The present study provides all of the neuroprotective mechanisms of polydatin in various NDDs. Additionally, the novel delivery systems of polydatin are provided regarding increasing its safety, solubility, bioavailability, and efficacy, as well as developing a long-lasting therapeutic concentration of polydatin in the central nervous system, possessing fewer side effects.

show abstract

Novel polydatin-loaded chitosan nanoparticles for safe and efficient type 2 diabetes therapy: In silico, in vitro and in vivo approaches

Cited by 45 publications

References 29 publications

Agriophyllum Oligosaccharides Ameliorate Diabetic Insulin Resistance Through INS-R/IRS/Glut4-Mediated Insulin Pathway in db/db Mice and MIN6 Cells

Agriophyllum Oligosaccharides Ameliorate Diabetic Insulin Resistance Through INS-R/IRS/Glut4-Mediated Insulin Pathway in db/db Mice and MIN6 Cells

Advances in Chitosan-Based Nanoparticles for Drug Delivery

The Neuroprotective Role of Polydatin: Neuropharmacological Mechanisms, Molecular Targets, Therapeutic Potentials, and Clinical Perspective

Contact Info

Product

Resources

About